This management guide of endocrine malignancies covers the risk factors, diagnosis, screening, and treatment of both thyroid and parathyroid cancers.
An analysis of thyroid cancer diagnosis and incidence in the United States suggests that there is an epidemic of diagnosis rather than an epidemic of thyroid cancer per se.
The FDA has approved sorafenib (Nexavar) for the treatment of metastatic differentiated thyroid cancer.
A combined dual inhibition of vascular endothelial growth factor (VEGF) and c-MET is showing promise in preventing tumor invasion and metastasis. The data thus far are in a laboratory model of pancreatic neuroendocrine cancer.
The review of surgical management of neuroendocrine tumors (NETs) of the gastrointestinal tract, authored by Huang, Poultsides, and Norton, is both comprehensive and accessible for readers of all backgrounds.